No child should be left without adequate protection against wild Dabrafenib research buy poliovirus (i.e. three doses of either vaccine). All OPV doses (mono-, bi- or trivalent) offered through supplementary immunization activities (SIAs), should also be provided. IPV may be offered as ‘catch up vaccination’ for children less than 5 years of age who have completed primary immunization with OPV. IPV can be given as three doses; two doses at two months interval followed by a third dose after 6 months. This schedule will ensure a long lasting protection against poliovirus disease. New poliovirus vaccination

schedule The primary schedule: • OPV (birth dose) + 3 doses of IPV at 6, 10 and 14 weeks + 2 doses of OPV at 6 & 9 months + IPV at 15–18 months (booster) + OPV at 5 years The alternative schedule: RG7422 cost • OPV at birth+ 2 doses of IPV at 8 and 16 weeks (i.e. 2 & 4 mo) + OPV at 6 & 9 mo + IPV at 15–18 mo + OPV at 5 years Catch-up schedule (IPV up to 5 years of age): • IPV can be given as 3 doses; 2 doses at 2 months interval followed by a 3rd dose after 6 months The committee has now recommended the following schedule

for routine Hepatitis-B vaccination in office practice for children: the first dose of a three-dose schedule should be administered at birth, second dose at 6 weeks, and third dose at 6 months (i.e. 0–6 week–6 month). This mafosfamide schedule is not only more closer to immunologically ideal and most widely used 0–1–6 months schedule, but also confirms to latest ACIP recommendations wherein the final (third or fourth) dose in the Hepatitis-B vaccine series should be administered no earlier than age 24 weeks and at

least 16 weeks after the first dose.47 It will replace the existing schedule of 0–6 week–14-week. However, the Hepatitis-B vaccine may be given through other schedules, considering the programmatic implications and logistic issues. The committee stresses the significance and need of birth dose. The committee reviewed the WHO recommendations regarding composition of flu vaccines for the southern and northern hemisphere for use in the 2012–2013 influenza seasons.48 and 49 For the northern hemisphere, it will contain the following strains: an A/California/7/2009 (H1N1) pdm09-like virus; an A/Victoria/361/2011 (H3N2)-like virus; and a B/Wisconsin/1/2010-like virus.48 The last two strains will be different from the last year’s vaccine for the region however; there will be no change in the composition of influenza vaccines for the southern hemisphere for 2012.49 Last year, the strains were similar for both the hemispheres. This will have impact on the types of vaccines to be used in coming season.